367-80-6

Basic information

• Product Name: Ethyl 4-fluoro-3-nitrobenzoate
• Synonyms: ETHYL 4-FLUORO-3-NITROBENZOATE;4-FLUORO-3-NITROBENZOIC ACID ETHYL ESTER;RARECHEM AL BI 0858;5-(Ethoxycarbonyl)-2-fluoronitrobenzene;Ethyl 4-fluoro-3-nitrobenzoate-2;Benzoic acid, 4-fluoro-3-nitro-, ethyl ester;4-fluoro-3-nitro-benzoate
• CAS NO: 367-80-6
• Molecular Formula: C₉H₈FNO₄
• Molecular Weight: 213.16
• Product Categories: FINE Chemical & INTERMEDIATES;Aromatic Esters
• Mol File: 367-80-6.mol
• Article Data: 29

Chemical Properties

• Melting Point: 45.3 °C
• Boiling Point: 312.3 °C at 760 mmHg
• Flash Point: 142.7 °C
• Appearance: /
• Density: 1.333 g/cm³
• Vapor Pressure: 0.000534mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethyl 4-fluoro-3-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-fluoro-3-nitrobenzoate(367-80-6)
• EPA Substance Registry System: Ethyl 4-fluoro-3-nitrobenzoate(367-80-6)

Safety Data

• Hazardous Substances Data: 367-80-6(Hazardous Substances Data)

Usage

General Description

Ethyl 4-fluoro-3-nitrobenzoate is a chemical compound with the molecular formula C9H8FNO4. It is a synthetic organic compound that contains a benzene ring with a fluorine atom and a nitro group attached to it. Ethyl 4-fluoro-3-nitrobenzoate is widely used in the pharmaceutical industry as a building block for the synthesis of various drugs and pharmaceutical products. It has also been used in research as a starting material for the development of new chemical compounds. Ethyl 4-fluoro-3-nitrobenzoate is known for its potential use as an intermediate in organic synthesis and has been the subject of various studies for its chemical and biological properties.

InChI:InChI=1/C9H8FNO4/c1-2-15-9(12)6-3-4-7(10)8(5-6)11(13)14/h3-5H,2H2,1H3

Upstream product

• 64-17-5 ethanol 
• 400-94-2 4-fluoro-3-nitrobenzoyl chloride 
• 16588-16-2 ethyl 4-chloro-3-nitrobenzoate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 64-67-5 diethyl sulfate 
• 109-63-7 boron trifluoride diethyl etherate 

Downstream Products

• 455-75-4 ethyl 3-amino-4-fluorobenzoate 
• 917237-08-2 4-(2-methoxycarbonyl-phenylsulfanyl)-3-nitro-benzoic acid ethyl ester 
• 913532-36-2 4-(3-hydroxymethyl-phenylamino)-3-nitro-benzoic acid ethyl ester 
• 935433-71-9 4-(4-fluoro-2-ethoxycarbonylphenylsulfanyl)-3-nitrobenzoic acid ethyl ester 
• 935873-06-6 ethyl 4-(3-methyl-3-nitro-butylamino)-3-nitro-benzoate 
• 312922-01-3 ethyl 4-[(2-methoxybenzyl)amino]-3-nitrobenzoate 
• 1175563-12-8 C₁₇H₁₅F₃N₂O₄ 
• 935433-67-3 4-(2-methoxycarbonyl-phenoxy)-3-nitrobenzoic acid ethyl ester 
• 440627-09-8 4-(2-carboxy-phenylsulfanyl)-3-nitro-benzoic acid 
• 440627-10-1 3-amino-4-(2-carboxy-phenylsulfanyl)-benzoic acid 
• 440627-14-5 11-oxo-10,11-dihydro-dibenzo [b,f][1,4]thiazepine-8-carboxylic acid 

Relevant articles and documents

Novel fluorescent benzimidazoles: Synthesis, characterization, crystal structure and evaluation of their anticancer properties

Background: The benzimidazole core structure is an interesting platform for drug discovery since it possess a wide spectrum of pharmacological activities such as antiviral, anti-inflammatory and anticancer. Previously the antiproliferative effect of novel

Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles

The enzyme butyrylcholinesterase (BChE) and the human cannabinoid receptor 2 (hCB2R) represent promising targets for pharmacotherapy in the later stages of Alzheimer's disease. We merged pharmacophores for both targets into small benzimidazole-based molecules, investigated SARs, and identified several dual-acting ligands with a balanced affinity/inhibitory activity and an excellent selectivity over both hCB1R and hAChE. A homology model for the hCB2R was developed based on the hCB1R crystal structure and used for molecular dynamics studies to investigate binding modes. In vitro studies proved hCB2R agonism. Unwanted μ-opioid receptor affinity could be designed out. One well-balanced dual-acting and selective hBChE inhibitor/hCB2R agonist showed superior in vivo activity over the lead CB2 agonist with regards to cognition improvement. The data shows the possibility to combine a small molecule with selective and balanced GPCR-activity/enzyme inhibition and in vivo activity for the therapy of AD and may help to rationalize the development of other dual-acting ligands.

Antituberculosis agents bearing the 1,2-disubstituted benzimidazole scaffold

Abstract: The emergence of drug-resistant strains in recent years has fueled the epidemic of tuberculosis. This necessitates the development of new chemical scaffolds to curb resistant tuberculosis for effective control of this disease. In this study, we have designed and synthesized two series of benzimidazole derivatives. Their antimycobacterial activities were initially evaluated using Mycobacterium tuberculosis H37RV strains. The most potent analog (6h) was further assessed using various drug-resistant M. tuberculosis strains. This report described the importance of benzimidazoles as new antitmycobacterial agents targeting both the M. tuberculosis H37RV as well as the drug-resistant-tuberculosis strains. The trifluoromethyl group which was essential for antimycobacterial activity was also highlighted. Graphical Abstract: Two series of benzimidazole derivatives and their antimycobacterial activities were evaluated using M. tuberculosis H37RV (MTB-H37RV) strains. Compound 6h was identified as the most potent among all synthesized compounds. The most potent analog was further assessed using various drug-resistant MTB strains. In addition, the trifluoromethyl was identified as an important substitution in giving good antimycobacterial effect. [InlineMediaObject not available: see fulltext.]